Trial to Assess Chelation Therapy (TACT)
Description:
EDTA chelation therapy involves repeated administrations of a synthetic amino acid to reduce
atherosclerotic plaque and other mineral deposits throughout the cardiovascular system.
Participants will be randomly assigned to receive 40 infusions of either the standard
chelation solution or placebo. The primary endpoint of this trial will be a composite of all
cause mortality, myocardial infarction, stroke, coronary revascularization, and
hospitalization for angina.
The results of TACT will provide either a significant positive result or an informative null
result upon which rational clinical decision-making and health policy can be based.
Condition:
Coronary Artery Disease
Treatment:
EDTA
Start Date:
September 2003
Sponsor:
Mt. Sinai Medical Center, Miami
For More Information:
https://clinicaltrials.gov/show/NCT00044213